Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.06), $0.08 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $173.1 million versus the consensus estimate of $156.2 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.